louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06620224: Exploring the Impact of VR-based Acupuncture Treatment on Patient Experience and Doctor-patient Interaction.
Official title: Exploring the Impact of Virtual Reality-based Traditional Chinese Acupuncture Treatment on Patient Experience and Doctor-patient Interaction.
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Acupuncture
Virtual Reality
Keywords: Traditional Chinese Medicine Acupuncture
Virtual Reality
Technology Acceptance Model
Doctor-Patient Interaction
Medical Quality
Lead sponsor: China Medical University Hospital
Sponsor class: OTHER
First posted: 2024-10-01
Enrollment: 20
Sex: ALL
Minimum age (years): 20
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: a non-randomized real world data
Primary purpose: SCREENING

Brief summary: Develop and establish a virtual reality acupuncture system, and introduce the technology acceptance model to systematically explore the impact of acupuncture treatment effectiveness and its related medical experience and doctor-patient interaction

Detailed description: Whether it\&#39;s Western medicine\&#39;s surgical treatment or traditional Chinese medicine\&#39;s acupuncture and acupotomy treatment, for patients preparing to undergo invasive treatment, pre-treatment explanations can improve patient compliance and reduce patient anxiety about disease treatment. The application of virtual reality systems in the medical field is mostly in preoperative training and medical education, while in the field of traditional Chinese medicine, it focuses on acupuncture teaching, with less evaluation of explanations before acupuncture treatment. Therefore, this study will develop and establish a virtual reality acupuncture system, and introduce the technology acceptance model to systematically explore the impact of acupuncture treatment effectiveness and its related medical experience and doctor-patient interaction

Eligibility criteria: Inclusion Criteria:

* general public and people see a doctor in the department of acupuncture

Exclusion Criteria:

* participant refusing the intervention of the virtual reality

Primary outcomes:
measure: Technology Acceptance Model
timeFrame: Immediately
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03336424: Urinary Disorders in Patients With Multiple Sclerosis: Invasive Vs Non-invasive Investigations.
Official title: Prospective Randomized Controlled Trial Comparing the Non-invasive vs the Invasive Investigations in Multiple Sclerosis Patients With Urinary Disorders.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Multiple Sclerosis
Urinary Bladder, Neurogenic
Urodynamics
Keywords: MS
Multiple sclerosis
urinary Bladder, Neurogenic
Urodynamics
Randomized controlled trial
Lead sponsor: Saint-Joseph University
Sponsor class: OTHER
First posted: 2017-11-08
Enrollment: 60
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Parallel study, where group A receives non-invasive investigations and group B receives Invasive investigations.
Primary purpose: DIAGNOSTIC

Brief summary: The objective of the study is to describe the current status of MS patients with urinary disorders in Lebanon, and to demonstrate whether invasive investigations improve the management of these patients compared to an optimal non-invasive approach.

Detailed description: All patients will be evaluated by an urologist, then randomized into 2 groups, the first group will benefit from non-invasive investigations and will be treated accordingly, the second group will benefit from an urodynamic assessment and will also be treated accordingly.

An evaluation will be made one month, 3 months and 6 months after the first visit.

Eligibility criteria: Inclusion Criteria:

* MS with urinary symptoms

Exclusion Criteria:

* BPH LUTS
* Bladder cancer
* prostate cancer
* urethral stenosis

Primary outcomes:
measure: urinary symptoms
timeFrame: 6 months
measure: urinary quality of life
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Beyrouth
country: Lebanon
facility: Saint Joseph University
Study officials:
affiliation: Saint-Joseph University
name: Elie EL HELOU, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04171024: Transcutaneous Diaphragm Electrical Stimulation in Critically Ill Patients
Official title: Transcutaneous Diaphragm Electrical StimuLAtion in Critically Ill Patients to Prevent Diaphragm Dysfunction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Critical Illness
Mechanical Ventilation
Intensive Care Unit
Keywords: Diaphragm dysfunction
Transcutaneous Electrical Stimulation
Intensive care unit
Mechanical ventilation
Lead sponsor: Groupe Hospitalier du Havre
Sponsor class: OTHER
First posted: 2019-11-20
Enrollment: 66
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study evaluates the effect of a transcutaneous electrical stimulation in critically ill patients compared to a sham electrical stimulation to decrease the incidence of diaphragm dysfunction before mechanical ventilation weaning.


Eligibility criteria: Inclusion Criteria:

* Patients intubated and ventilated for at least 24 h
* Patients who were expected to have at least 48h after inclusion

Exclusion Criteria:

* Patient with pacemaker
* Patient under neuro muscular blocker
* Patient post thoracic or abdominal surgery
* Patient with BMI more than 35 kg/m²
* Patient with degenerative neurological pathology
* Patient with cutaneous lesion may be interfered with probes
* Patient with chronic loss of autonomy
* Patient hospitalized more than 72 hours before ICU admission
* Patient with severe chronic obstructive pulmonary disease (FEV1 \< 30%)
* Patient with decision to withhold life-sustaining treatment

Primary outcomes:
measure: Diaphragm Thickening fraction
timeFrame: Once, At the start of the spontaneous breathing trial
Secondary outcomes:
measure: Diaphragm atrophy
timeFrame: Once a day under mechanical ventilation, throughout the study
measure: Inspiratory strength
timeFrame: Once, At the start of the spontaneous breathing trial
measure: Cough strength
timeFrame: Once, At the start of the spontaneous breathing trial
measure: Proportion of patients successfully liberated from the ventilator
timeFrame: After 3 days of spontaneous breathing
Other outcomes:
Locations:
city: Le Havre
country: France
facility: Medrinal
Study officials:
References:
Clinical trial NCT05025124: Entia Liberty: Accuracy and Precision
Official title: Entia Liberty: Analytical Performance Validation - Accuracy and Precision
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cancer
Lead sponsor: Entia Ltd
Sponsor class: INDUSTRY
First posted: 2021-08-27
Enrollment: 530
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: No participants will be recruited. Samples used are from excess venous bloods from the Christie haematology laboratory

Brief summary: This study forms part of Entia's clinical evidence for regulatory submission. This study evaluates Entia Liberty's performance claims with venous blood compared to the gold standard clinical laboratory haematology analysers. Excess blood flagged by the laboratory meeting our requirements will be tested on the Entia Liberty device and have its results compared against the laboratory results. Samples will also be flagged for precision testing (same blood sample, split into 10 Entia Liberty samples).


Eligibility criteria: Inclusion Criteria:

* Age \>18 years old
* Currently receiving standard of care systemic anti-cancer therapy (chemotherapy, immunotherapy, endocrine and targeted therapy) for solid organ malignancy and has received at least one cycle
* Blood samples that have been stored in K2-EDTA vacutainers only
* For Accuracy testing: Samples covering 75% of parameter ranges (Neutrophils: 0.5-7.5 x 109/L, Platelets: 20-450 x 109/L, Haemoglobin: 70-180 g/L), These will be determined by a gold standard analyser which has been recently calibrated.
* Reliability study: Level range per parameter. These will be determined by a gold standard analyser which has been recently calibrated.
* Neutrophils (We assume WBC to behave similarly in the same ranges) Low: 0.5-1.2 x 109/L (3 samples), 1.2-2 x 109/L (2 samples) Normal: 2-7 x 109/L (3-4 samples) High: 7-12 x 109/L (1-2 samples)
* Platelets Low: 50-150 x 109/L (5 samples) Normal: 150-400 x 109/L (3 - 4 samples) High: \>400 x 109/L (1-2 samples)
* Haemoglobin Low: \<120 g/L (5 samples) Normal: 120-170 g/L (3 - 4 samples) High: \>170 g/L (1-2 samples)

Exclusion Criteria:

* History of haematological malignancy

Primary outcomes:
measure: To obtain the Total Error per parameter from the results of the Entia Liberty device
timeFrame: 3 months
measure: To obtain the linearity per parameter from the results of the Entia Liberty device
timeFrame: 3 months
measure: To obtain the bias per parameter from the results of the Entia Liberty device
timeFrame: 3 months
measure: To obtain the precision per parameter from the results of the Entia Liberty device
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Leeds
country: United Kingdom
facility: Leeds Teaching Hospitals NHS Trust
Study officials:
References:
Clinical trial NCT05342324: Optical Coherence Tomography Angiography and Choroidal Osteoma
Official title: Optical Coherence Tomography Angiography in Choroidal Osteoma: a Quantitative Evaluation of Choriocapillary Vessel Density
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Choroidal Osteoma, Bilateral
Lead sponsor: Federico II University
Sponsor class: OTHER
First posted: 2022-04-22
Enrollment: 28
Sex: ALL
Minimum age (years): 50
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The participans were older than 50 years with choroidal osteoma. They did not present other ophthalmological diseases.

Brief summary: This study evaluates the vessel density of choriocapillary vascular network in eyes affected by choroidal osteoma and in eyes complicated by choroidal neovascularization, using optical coherence tomography angiography.

Detailed description: The choroidal osteoma is a rare benign tumor of choroid, it is bilateral in 10%-25% of cases, affecting usually young women. Previous studies evaluated the morphologic characteristics of tumor-related vasculatures, described as a seafun vascular networks, but none focused on study of vessel density of coriocapillary.

The aim of this study is to investigate the potential role of the optical coherence tomography angiography (OCTA) in evaluating the choriocapillary vessel density in order to individuate the changes of this vascular network that may influence the onset of choroidal neovasculariztion.

Therefore, OCTA could be useful in the clinical management of the choroidal osteoma

Eligibility criteria: Inclusion Criteria:

* age older than 50 years
* diagnosis of choroidal osteoma
* absence of history of vitreoretinal and vascular retinal diseases

Exclusion Criteria:

* age younger than 50 years
* no diagnosis of choroidal osteoma
* presence of history of vitreoretinal and vascular retinal diseases

Primary outcomes:
measure: Study of vessel density of the choriocapillary in patients affected by choroidal osteoma .
timeFrame: 7 years
Secondary outcomes:
Other outcomes:
Locations:
city: Naples
country: Italy
facility: Federico II University
state: Napoli
Study officials:
affiliation: Università Federico II
name: Gilda Cennamo
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04592224: Cancer Information Your Way: Get What You Need to Make Your Decisions
Official title: Cancer Information Your Way: Get What You Need to Make Your Decisions - a Qualitative Study of Decision Making by Patients With Lower Health Literacy Receiving Care for Incurable Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cancer
Keywords: Health literacy
Lead sponsor: University of Southampton
Sponsor class: OTHER
First posted: 2020-10-19
Enrollment: 21
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients diagnosed with incurable malignancy of any site, identified by their healthcare professionals as potentially having difficulties with health literacy

Brief summary: People diagnosed with cancer may face many difficult decisions regarding their care and preferences. This may be particularly challenging when the cancer cannot be cured. It is therefore hugely important that patients have the information they need so that they can be involved in these decisions and in their care.

This qualitative interview study aims to hear from patients who might have found that the information they were given wasn't easy to understand, or who haven't been able to get involved in their care as much as they would have liked. We hope to learn from these experiences in order to improve the way patients are given information and supported to become involved in their care.

Detailed description: Participants will be identified by healthcare professionals and invited to take part in a single interview either by phone or video call, lasting around an hour.

Interviews will be semi-structured and follow a topic guide, exploring how participants have been given information, how decisions have been made, and any particular challenges they may have faced.

Consent will also be sought for collection of demographic and disease data from the participant's medical record

Eligibility criteria: Inclusion criteria:

* Diagnosis of incurable malignancy of any site (as identified by their treating oncologist and may be characterised by eligibility for or receipt of treatment with palliative intent)
* Identified by a member of the healthcare team as potentially having difficulties with health literacy
* Capacity to provide informed consent
* English as the main language

Primary outcomes:
measure: Semi-structured interviews
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Poole
country: United Kingdom
facility: Poole Hospital
state: Dorset
Study officials:
affiliation: Poole Hospital
name: Chloe E Holden, MBBCh
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02065024: Food Matrix and Genetic Variability as Determinants of Bioavailability and Biological Effects of Beta-cryptoxanthin and Phytosterols
Official title: Food Matrix and Genetic Variability as Determinants of the Bioavailability and Biological Effects of a B-cryptoxanthin and Phytosterols-enriched Beverage; In Vitro and in Vivo Evaluation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Hypercholesterolemia
Osteoporosis
Keywords: b-cryptoxanthin
plant sterols
serum Cholesterol
bone turnover markers
Lead sponsor: Puerta de Hierro University Hospital
Sponsor class: OTHER
First posted: 2014-02-17
Enrollment: 40
Sex: FEMALE
Minimum age (years): 45
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: Regular consumption of a beverage containing β-cryptoxanthin (b-Cx) and plant sterols (Ps) has been shown to exert a synergic effect in reducing cardiovascular risk and bone remodeling markers (formation and resorption). The present project aims to assess the influence of technological treatment and genetic variability on the bioavailability and the health effects of the added components (Ps, b-Cx), in particular to their potential role in prevalent disorders.In vitro and in vivo studies will be carried out to this effect. In vitro and in vivo studies (human intervention study) will be performed and cardiovascular, bone turnover and inflammation markers will be evaluated. Additionally, an in vitro colonic fermentation model and cell cultures will be used to explore anticarcinogenic effects and potential cytotoxicity.


Eligibility criteria: Inclusion Criteria:

* Post-menopausal women; mild hypercholesterolemia

Exclusion Criteria:

* Use of cholesterol lowering drugs, hormonal therapy, vitamin and herbs supplements use

Primary outcomes:
measure: serum response of B-cryptoxanthin
timeFrame: 6 weeks of intervention
measure: Serum response of phytosterols
timeFrame: 6 weeks
Secondary outcomes:
measure: Serum lipid profile
timeFrame: 6 weks of intervention
measure: bone resorption markers
timeFrame: 6 weeks
measure: interleukins
timeFrame: 6 weeks
measure: Serum C-reactive protein
timeFrame: 6 weeks
measure: Bone formation markers
timeFrame: 6 weeks
measure: Sterols faecal levels
timeFrame: 6 weeks
measure: Erythrocytes for eryptosis evaluation
timeFrame: 6 weeks
Other outcomes:
measure: Intestinal transporters polymorphisms,
timeFrame: Baseline
Locations:
city: Majadahonda (Madrid)
country: Spain
facility: Hospital Universitario Puerta de Hierro-Majadahonda
state: Madrid
Study officials:
References:
citation: Cuevas-Tena M, Bermudez JD, Silvestre RLA, Alegria A, Lagarda MJ. Impact of colonic fermentation on sterols after the intake of a plant sterol-enriched beverage: A randomized, double-blind crossover trial. Clin Nutr. 2019 Aug;38(4):1549-1560. doi: 10.1016/j.clnu.2018.08.012. Epub 2018 Sep 7.
Clinical trial NCT06976424: Comparison of a Face Cream Plus a Laser Procedure and Face Cream Alone in Treatment of Excessive Face Hairs in Female
Official title: Comparison of Eflornithine Cream Combined With Intense Pulsed Light Versus Intense Pulsed Light Alone for Hirsutism in Women
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE4
Conditions: Hirsuitism
Keywords: Hirsuitism
IPL
Eflornithine
Lead sponsor: Khyber Teaching Hospital
Sponsor class: OTHER
First posted: 2025-05-16
Enrollment: 122
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study compares the effects of a cream alone and a combined effect of cream and laser for the treatment of excessive facial hairs in women .

Detailed description: Hirsuitism refers to excessive terminal hairs in females, following a distribution pattern typically associated with male. It is associated with either increase response of hair follicles to androgen or either increase level of circulating androgens.The treatment options available are topical creams like eflornithine and laser treatments for hair removal. This study aims to conduct the comparison of a eflornithine cream and intense pulsed light laser versus eflornithine cream alone for the treatment of excessive facial hairs.

Eligibility criteria: Inclusion Criteria:

Gender (Female) Age between 18-45 Years Women with hirsutism as mentioned in the operational definition

Exclusion Criteria:

Pregnant women Women with severe acne Women with immunodeficiency

Primary outcomes:
measure: Efficacy of treatment
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Peshawar
country: Pakistan
facility: Khyber Teaching Hospital
state: Kpk
city: Peshawar
country: Pakistan
facility: Khyber Teaching Hospital
state: KPK
city: Peshawar
country: Pakistan
facility: Khyber Teachinng Hospital
state: KPK
Study officials:
References:
Clinical trial NCT05120024: Multicenter Study of Safety and Efficacy of Prolgolimab in Patients With Advanced Melanoma in Routine Clinical Practice
Official title: Multicenter Non-interventional Retro- and Prospective Safety and Efficacy Study of Prolgolimab (Forteca - Anti-PD1) in Patients With Advanced Melanoma (FOrteca Real Practice Assessment)
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Advanced Melanoma
Lead sponsor: MelanomaPRO, Russia
Sponsor class: OTHER
First posted: 2021-11-15
Enrollment: 350
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with advanced melanoma, who were treated by prolgolimab (anti-PD1) in routine clinical practice in Russian Federation

Brief summary: Describe the safety, tolerability, efficacy and approaches to prescribing prolgolimab in the standard dosing regimen of 1 mg / kg every 2 weeks in patients with advanced melanoma in routine practice.

Prolgolimab (Forteca, formerly BCD 100) is an IgG1 anti-PD-1 (programmed cell death protein 1) monoclonal antibody containing the Fc-silencing 'LALA' mutation.

Detailed description: Describe the safety and tolerability of using Prolgolimab at a standard dosage regimen of 1 mg / kg every 2 weeks.

Describe the efficacy of prolgolimab 1 mg / kg every 2 weeks in patients with metastatic or inoperable melanoma in routine practice, based on the following indicators: Progression-free survival (time from first dose of prolgolimab to disease progression or death for any reason); Overall survival (time from receiving the first dose of prolgolimab to death for any reason); Objective response rate (proportion of patients with a complete or partial response to prolgolimab therapy).

Eligibility criteria: Inclusion Criteria:

Histological confirmed melanoma Advanced stage (unresectable III or metastatic IV) Treated by at least one therapy line including prolgolimab in routine practice -

Exclusion Criteria:

- Patient participation in any interventional clinical study.

Primary outcomes:
measure: The incidence of adverse events during prolgolimab therapy
timeFrame: 2 years
measure: Objective response rate
timeFrame: 3 years
Secondary outcomes:
measure: Progression free survival (PFS)
timeFrame: 3 years
measure: Overall survival (OS)
timeFrame: 3 years
Other outcomes:
Locations:
city: Moscow
country: Russian Federation
facility: N.N. Blokhin National Medical Research Center of Oncology
Study officials:
affiliation: MelanomaPRO, Russia
name: Kristina Orlova, MD PhD
role: STUDY_CHAIR
References: